Analyst Raises Price Target on Kimberly-Clark (KMB) by $3

Core Viewpoint - Kimberly-Clark Corporation is recognized as a strong investment opportunity, particularly in the context of dividend stocks, despite challenges related to its acquisition of Kenvue [1][5]. Financial Performance - On January 27, Kimberly-Clark reported quarterly profits that exceeded expectations, driven by effective cost controls and steady demand for essential products like Huggies and Kleenex across key markets including North America and China [3]. Strategic Decisions - The company has made significant operational adjustments in recent years, including workforce reductions and exiting lower-margin sectors such as private-label diapers and personal protective equipment, which have helped maintain profit margins [4]. - Management has also focused on expanding value-oriented product lines, introducing lower-priced options that retain features associated with premium brands, aiming to appeal to budget-conscious consumers [4]. Acquisition and Future Strategy - Kimberly-Clark is undergoing a strategic transformation to position itself as a global consumer health business, highlighted by its $40 billion acquisition of Kenvue, which is expected to close by year-end and is a crucial element of the company's long-term strategy [5]. Analyst Insights - UBS analyst Peter Grom raised the price target for Kimberly-Clark to $110 from $107 while maintaining a Neutral rating, indicating that while the core business remains stable, concerns related to Kenvue may persist [2].